NewsTechCrunch AI
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Wednesday, September 23, 2026
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Daily healthcare AI brief
Get the free healthcare AI briefing
One concise briefing built from reporting, research, policy, blogs, videos, and full podcast transcripts.
Free. No account needed. Unsubscribe anytime. Already subscribed? Sign in to save and personalize.